Insilico Medicine Reports First Full-Period Profit with 06.3M Revenue in H1 2026
Clinical-stage generative AI drug discovery company Insilico Medicine reported a net profit of $35.54 million and adjusted net profit of $51.23 million on total revenue of $106.3 million for the first half of 2026. The financial results, disclosed in the company's interim report following its listing on the Hong Kong Stock Exchange in late 2025, represent the first full-period profitability recorded by an AI-focused biopharmaceutical platform company. The company achieved positive operating cas
1 min